Curative by Design™
High Probability (HP) neoantigens are the unique amino acid sequences (peptides) within an HCP target protein that have a high likelihood of immune (HLA) presentation on the tumor cell surface and recognition by killer T cells.
Sets of HCP neoantigens for each target protein become efficient peptide tools for the isolation of the surface molecules used by
T cells to recognize the neoantigens.
±±The HCP therapy can include T cells to a second neoantigen and/or the co-engineering of an immune modulator such as IL-12 to enhance HCP T cell response.
The deliberate, cancer-specific targeting of a HCP T Cell Therapy has the ability to permanently eliminate the solid tumor with minimized off-target damage to normal tissue.